Trial Profile
Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Methotrexate; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Lymphoid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 23 Apr 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 04 Mar 2017 New trial record